Certolizumab pegol (Cimzia®) gained FDA approval in September/October 2013 for two new indications, adults with active psoriatic arthritis (PsA) and adults with active ankylosing spondylitis (AS). Already approved for adults with Crohn’s Disease and Rheumatoid Arthritis, certolizumab pegol (CZP) is a humanized TNF-α monoclonal antibody.
Approval for golimumab (which will by marketed under the trade name Simponi) was granted this week by the U.S. Food and Drug Administration. The drug received approval for the treatment of moderate to severe RA (in conjunction with methotrexate), active psoriatic arthritis (as monotherapy or with methotrexate), and active ankylosing spondylitis at a dose of […]
There are currently no biologic treatment options available for patients with psoriatic arthritis (PsA) who are non-responsive to traditional non-biologic DMARDs and TNF inhibitors. Interleukins (IL) 12 and 23 have been implicated in the pathogenesis of plaque psoriasis. A humanized monoclonal antibody directed against these cytokines, ustekinumab, has demonstrated efficacy in the treatment of psoriasis […]